Novoste appoints Getz for Pacific Rim:
This article was originally published in Clinica
Executive Summary
Australian company Getz has agreed to oversee the commercialisation and distribution of Novoste's Beta-Cath system in Australia and New Zealand following a three- year agreement. The product is designed to inhibit restenosis by delivering radiation therapy to the artery immediately after an angioplasty procedure (see Clinica, No 866, p 15). According to Norcross, Georgia-based Novoste, the Beta-Cath system is the first vascular brachytherapy device to become commercially available in Australia. It is already on sale in Europe and undergoing clinical trials in the US.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.